Search | Clinical Trials Finder

Conditions: Chronic Spontaneous Urticaria
Interventions: CDX-0159, Normal Saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more

Conditions: Atopic Dermatitis
Interventions: MM36 topical ointment, 1%; Drug
Lead sponsor: Medimetriks Pharmaceuticals, Inc; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Fremont, California • Irvine, California • San Diego, California + 7 more

Conditions: Atopic Dermatitis
Interventions: ASLAN004, ASLAN004 Placebo; Drug
Lead sponsor: ASLAN Pharmaceuticals; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Fremont, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Asthma
Interventions: Salbutamol HFA-134a, Salbutamol HFA-152a; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 38
States / cities: North Hollywood, California • San Mateo, California • Aventura, Florida + 32 more

Conditions: Asthma
Interventions: indacaterol maleate; Drug
Lead sponsor: Novartis; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: ART6043, Olaparib; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 4 more

Conditions: Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions: TBAJ-876, Midazolam, Digoxin; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Chronic Spontaneous Urticaria
Interventions: AK006 IV; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • Bakersfield, California • Upland, California + 6 more

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen/naphazoline, Naphazoline, Ketotifen, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Ovarian Cancer
Interventions: Olaparib tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Duarte, California • Newport Beach, California • Roseville, California + 10 more

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Asthma
Interventions: Mepolizumab, Placebo, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more

Conditions: Allergic Conjunctivitis
Interventions: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma, Breast Cancer
Interventions: Prototype intraoperative handheld gamma camera (pIHGC), Lymphoscintigraphy with intraoperative gamma probes (GP), radioactive Tc99M; Device · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: Placebo, Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Drug Interactions
Interventions: Telotristat etiprate, Midazolam; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more

Conditions: Asthma
Interventions: AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 21
States / cities: Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more

Conditions: Severe Asthma
Interventions: Verekitug (UPB-101), Placebo; Drug
Lead sponsor: Upstream Bio Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 55
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 47 more

Conditions: Healthy Participants, Chronic Spontaneous Urticaria
Interventions: AK006-IV, Placebo-IV, AK006-SC, Placebo-SC; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 121
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more

Conditions: Stroke
Interventions: Non-Interventional; Other
Lead sponsor: Valtari Bio; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cincinnati, Ohio • Austin, Texas

Conditions: Hereditary Angioedema (HAE)
Interventions: DX-2930, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: TERN-201, Placebo; Drug · Other
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more

Search by objective public record fields.

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy

Nebivolol in the Supine Hypertension of Autonomic Failure

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Validation of Sensitivity and Specificity of a Multi-Omic Precision Diagnostic for Acute Stroke Evaluation

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis